|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Roche Holding AG, a leading research-focused pharmaceutical and diagnostics company. |
|---|---|
| Transferring Party | Therapeutic Human Polyclonals, Inc., a privately-owned biotechnology company focused on antibody research. |
| Sector | Diagnostics |
| Date | April 2, 2007 |
| Analysis Builds on Roche's strength in therapeutic antibodies and adds to its R&D organization. THP developed a unique transgenic mammalian platform to create human antibodies, enhancing the efficacy of both monoclonal and polyclonal antibody therapeutics. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |